Cosmetic Outcome after Interstitial Brachytherapy Accelerated Partial Breast Irradiation Is Related to the Location of the Lumpectomy Cavity

Cosmetic outcome after breast conservation therapy for breast cancer is a major outcome measure of importance. Strict criteria for excellent (E), good (G), fair (F), and poor (P) grades have been established, and many investigators group these scores as “acceptable” if they are G or E, and “unacceptable” if they are F or P. In order to evaluate the influence of tumor location on cosmetic outcome after accelerated partial breast irradiation (APBI) using multicatheter interstitial brachytherapy (MIB), we scored cosmesis for all patients who had at least 2 years of follow-up by the quadrant of the breast of the lumpectomy cavity.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

This report details our experience using accelerated partial breast irradiation (APBI) as a component of salvage breast conserving treatment.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Breast conserving therapy is frequently used to treat early stage breast cancer but the protracted length of whole breast irradiation has made it an unattractive option for some patients. Accelerated partial breast irradiation (APBI) is used to treat the lumpectomy cavity alone in a shorter amount of time, conventionally in 10 fractions twice daily over 5 days. The SenoRx study opened by Contura, was a multi-site prospective phase II non-randomized dose-escalation trial for APBI using a multi-lumen balloon 3 or 4 fractions over 2 days.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Abstract Accelerated partial breast irradiation (APBI) is an increasingly utilized modality for early stage breast cancer as part of breast conservation therapy (BCT). There remains concern regarding local recurrence, requiring more frequent post‐radiation surveillance imaging. The purpose of this study is to determine clinical significance of frequent surveillance in this perceived higher risk population. Patients treated at a community academic medical center from 2005 to 2013 with partial breast radiation were retrospectively identified. All patients were treated with lumpectomy followed by balloon based APBI. Diagnos...
Source: The Breast Journal - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
We report our experience and outcomes with accelerated partial breast brachytherapy (APBI) for early stage breast cancer, both invasive and non-invasive breast cancers. The cancer was treated with breast-conserving therapy consisting of a lumpectomy followed by accelerated partial breast irradiation.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsEarly results from this multi-center trial demonstrate that IORT using the Xoft Axxent eBx System at the time of breast conservation surgery continues to be a promising treatment option for early stage breast cancer. The short course of radiation therapy for select patients has excellent to good cosmetic results and a low rate of high-grade adverse events and recurrences.FundingFunded by Xoft, Inc., a subsidiary of iCAD, Inc.AcknowledgementMedical writing support from Dr. Theresa E. Singleton, Singleton Science, LLC.Citation Format: Gampenrieder SP, Rinnerthaler G, Pulverer W, Weinhäusel A, Hufnagl C, Hackl...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
ConclusionsEarly results from this multi-center trial suggest that IORT as a tumor-bed boost using the Xoft Axxent eBx System at the time of breast conservation surgery is safe and has low morbidity. To date, the majority of participants receiving an unplanned IORT boost have had excellent to good cosmetic results and the majority of adverse events have been low-grade.FundingFunded by Xoft, Inc., a subsidiary of iCAD, Inc.Citation Format: Kasimir-Bauer S, Bittner A-K, Goebel A, Hoffmann O, Browne AJ, Rauner M, Hofbauer LC, Wimberger P, Kimmig R, Rachner TD. Serum levels of RANKL are increased in primary breast cancer patie...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
This study sought to evaluate local control and cosmetic results of delivering boost doses using a high-dose-rate (HDR) brachytherapy (HDRBT) in breast cancer conservative treatment.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original article Source Type: research
This study sought to evaluate local control and cosmetic results of delivering boost doses using a high-dose-rate (HDR) brachytherapy (HDRBT) in breast cancer conservative treatment. METHODS: We included 621 T1-T2, N0-N1 breast cancer patients who underwent lumpectomy, external irradiation (44Gy over 5weeks), and a boost dose of two fractions of 5Gy to the tumor bed by means of HDR iridium brachytherapy. Implantation was performed during the lumpectomy or 2-3weeks after external irradiation. Population characteristics were as follows: pTis=11.6%; pT1=63.4%; pT2=25.0%; median tumor size=1.5cm; histology: ductal carcino...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Authors: Akhtari M, Teh BS Abstract The management of localized breast cancer has changed dramatically over the past three to four decades. Breast-conserving therapy, which involved lumpectomy followed by adjuvant irradiation, is now widely considered the standard of care in women with early-stage breast cancer. Accelerated partial breast irradiation (APBI), which involves focal irradiation of the lumpectomy cavity over a short period of time, has developed over the past two decades as an alternative to whole breast irradiation (WBI). Multiple APBI modalities have been developed including brachytherapy, external be...
Source: Chinese Journal of Cancer - Category: Cancer & Oncology Tags: Chin J Cancer Source Type: research
Objectives: To describe observations of one-year follow-up of subjects treated on a multi-center, non-randomized study with a single fraction of intra-operative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy System® (eBx®) immediately following surgical resection of early stage breast cancer.Methods: Two-hundred forty three (243) subjects were treated at seventeen (17) US hospitals. Upon meeting the inclusion/exclusion criteria, patients underwent partial mastectomy, placement of a balloon applicator suitable to the surgical bed in the lumpectomy cavity and inflated with saline (3...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Brachytherapy | Breast Cancer | Breast Conservation Surgery | Breast Lumpectomy | Cancer | Cancer & Oncology | Lumpectomy